HERON THERAPEUTICS, INC. /DE/ - 8-K Filing

Heron Therapeutics reports Q3 2026 net revenue of $35.3 million and announces definitive agreement for CorMedix Therapeutics to acquire substantially all assets. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $HRTX

Read the full article at SEC EDGAR

More Regulatory news